Title: High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
Authors: Willemze, Roelof ×
Suciu, Stefan
Meloni, Giovanna
Labar, Boris
Marie, Jean-Pierre
Halkes, Constantijn J M
Muus, Petra
Mistrik, Martin
Amadori, Sergio
Specchia, Giorgina
Fabbiano, Francesco
Nobile, Francesco
Sborgia, Marco
Camera, Andrea
Selleslag, Dominik L D
Lefrère, Francois
Magro, Domenico
Sica, Simona
Cantore, Nicola
Beksac, Meral
Berneman, Zwi
Thomas, Xavier
Melillo, Lorella
Guimaraes, Jose E
Leoni, Pietro
Luppi, Mario
Mitra, Maria E
Bron, Dominique
Fillet, Georges
Marijt, Erik W A
Venditti, Adriano
Hagemeijer-Hausman, Anne
Mancini, Marco
Jansen, Joop
Cilloni, Daniela
Meert, Liv
Fazi, Paola
Vignetti, Marco
Trisolini, Silvia M
Mandelli, Franco
de Witte, Theo #
Issue Date: Jan-2014
Publisher: Grune & Stratton
Series Title: Journal of Clinical Oncology vol:32 issue:3 pages:219-28
Abstract: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.
ISSN: 0732-183X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Department of Human Genetics - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science